Factor XI and XIa inhibition: a new approach to anticoagulant therapy
Research article published in The British journal of cardiology (2024)
Abstract
Factor (F) XI or XIa inhibition has Fattracted interest due to the protection from thrombotic events and minimal bleeding tendency observed in FXI-deficient individuals. The prospect of uncoupling the management of thrombosis from the bleeding risk inadvertently associated with current therapy inspired the development of agents directed towards this step in the coagulation process. This review describes the physiological rationale behind FXI/FXIa inhibition and the pharmacological properties of existing FXI/FXIa inhibitors. It also explores the potential clinical use of these agents in various thromboembolic pathologies, predominantly through the phase II clinical trials conducted so far comparing them to current anticoagulant therapy or placebo.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed clinical and outcomes research relevant to anticoagulation, leech therapy, and microsurgical flap management. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This review explains the physiological rationale for inhibiting coagulation factor XI/XIa, motivated by the observation that FXI-deficient individuals appear protected from thrombosis while showing minimal bleeding tendency, and surveys the pharmacology of existing FXI/FXIa inhibitors and their potential use across thromboembolic conditions, drawing on phase II trials conducted so far against current anticoagulants or placebo. It is relevant to the leech-secretome drug-discovery narrative because it reflects the same overarching goal that animates interest in leech-derived molecules: uncoupling antithrombotic benefit from bleeding risk. As a review summarizing early-phase (phase II) and preclinical reasoning, it does not establish proven efficacy or safety, the FXI/FXIa agents remain investigational per the abstract, and the article does not address hirudotherapy directly.
Citation
Factor XI and XIa inhibition: a new approach to anticoagulant therapy.
Sammut et al. · The British journal of cardiology, 2024
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026